Publication | Closed Access

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Breast OncologyParp Inhibitor VeliparibMedicinePharmacologyBreast CancerTriple-negative Breast CancerCancer TreatmentOncologyRadiation OncologyNeoadjuvant Chemotherapy